Plus Therapeutics Regains Nasdaq Compliance, Resolving Delisting Risk

summarizeSummary

Plus Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, effectively resolving a prior delisting risk following a recent reverse stock split.

check_boxKey Events

• Nasdaq Compliance Regained

  Plus Therapeutics, Inc. received written notice from The Nasdaq Stock Market LLC confirming it has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).

• Delisting Risk Resolved

  This notification resolves the previously disclosed Nasdaq delisting risk, which was a significant concern for the company's continued listing.

• Follows Reverse Stock Split

  Compliance was achieved after a one-for-twenty-five reverse stock split, which became effective on April 2, 2026.

auto_awesomeAnalysis

This filing is highly important as it confirms Plus Therapeutics has successfully resolved the Nasdaq minimum bid price deficiency, a significant risk previously highlighted in the company's 10-K. Regaining compliance removes a major overhang and potential delisting threat, which is crucial for maintaining investor confidence and market liquidity. While the compliance was achieved through a reverse stock split, the successful outcome of retaining the Nasdaq listing is a positive development for the company's operational stability and access to capital markets.